| Columbus Regional Health Physicians, Llc | |
|
2400 17th St Columbus IN 47201 | |
| (812) 373-3025 | |
| Not Available |
| Full Name | Columbus Regional Health Physicians, Llc |
|---|---|
| Speciality | Internal Medicine |
| Location | 2400 17th St, Columbus, Indiana |
| Authorized Official Name and Position | Thomas A Sonderman (CMO) |
| Authorized Official Contact | 8123348958 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Columbus Regional Health Physicians, Llc Po Box 775383 Chicago IL 60677-5383 Ph: (812) 375-3000 | Columbus Regional Health Physicians, Llc 2400 17th St Columbus IN 47201 Ph: (812) 373-3025 |
| NPI Number | 1336510098 |
|---|---|
| Provider Enumeration Date | 10/07/2015 |
| Last Update Date | 12/17/2019 |
| Medicare PECOS PAC ID | 1052612314 |
|---|---|
| Medicare Enrollment ID | O20151211000054 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1336510098 | NPI | - | NPPES |
| Provider Name | Cristin D Mckinley |
|---|---|
| Provider Type | Practitioner - Registered Dietitian Or Nutrition Professional |
| Provider Identifiers | NPI Number: 1922247956 PECOS PAC ID: 4688575798 Enrollment ID: I20040120000640 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Brian Michael Kline |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1114954922 PECOS PAC ID: 1557256641 Enrollment ID: I20040218000138 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Mark Edward Hatfield |
|---|---|
| Provider Type | Practitioner - Cardiovascular Disease (cardiology) |
| Provider Identifiers | NPI Number: 1619046158 PECOS PAC ID: 1355321753 Enrollment ID: I20040726000359 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Jamie Nicole Hannah |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1790778785 PECOS PAC ID: 0547230161 Enrollment ID: I20040729001148 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Melinda W Hunnicutt |
|---|---|
| Provider Type | Practitioner - Cardiovascular Disease (cardiology) |
| Provider Identifiers | NPI Number: 1710053616 PECOS PAC ID: 0749254209 Enrollment ID: I20040821000204 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Patrick Pennington |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1730173626 PECOS PAC ID: 9133194137 Enrollment ID: I20040901001059 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Xabier Beristain |
|---|---|
| Provider Type | Practitioner - Neurology |
| Provider Identifiers | NPI Number: 1124025135 PECOS PAC ID: 0840268157 Enrollment ID: I20040923000441 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Lawrence S Klein |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1093773467 PECOS PAC ID: 3274509328 Enrollment ID: I20041005000108 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Kathleen Ann Smith |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1841392883 PECOS PAC ID: 7618936840 Enrollment ID: I20041005000222 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Tatiana Dee Doran |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1003948100 PECOS PAC ID: 5890752240 Enrollment ID: I20041216000848 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Anton J Koopman |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1538182035 PECOS PAC ID: 6901858620 Enrollment ID: I20050210000579 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Carlos Vieira |
|---|---|
| Provider Type | Practitioner - General Surgery |
| Provider Identifiers | NPI Number: 1164463949 PECOS PAC ID: 4587617279 Enrollment ID: I20050222000772 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Sueann Thomas |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1417959917 PECOS PAC ID: 8527000363 Enrollment ID: I20050523000854 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Laura Ann Nelson |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1124169362 PECOS PAC ID: 3072558246 Enrollment ID: I20050628000582 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Tracy L Salinas |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1053303032 PECOS PAC ID: 6901836048 Enrollment ID: I20050817001023 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Dale E Guse |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1700843489 PECOS PAC ID: 8527098664 Enrollment ID: I20050817001044 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Tara Roeder |
|---|---|
| Provider Type | Practitioner - Emergency Medicine |
| Provider Identifiers | NPI Number: 1194770016 PECOS PAC ID: 2264462274 Enrollment ID: I20050819000160 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Julie Lynn Tuttle |
|---|---|
| Provider Type | Practitioner - Physical Medicine And Rehabilitation |
| Provider Identifiers | NPI Number: 1467411876 PECOS PAC ID: 4981619830 Enrollment ID: I20060214000072 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Abdul Jabbar |
|---|---|
| Provider Type | Practitioner - Gastroenterology |
| Provider Identifiers | NPI Number: 1437141835 PECOS PAC ID: 8527952035 Enrollment ID: I20070307000002 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Tricia K Gifford |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1326029158 PECOS PAC ID: 8921001173 Enrollment ID: I20070515000417 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Ilya Schwartzman |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1144252552 PECOS PAC ID: 9739286220 Enrollment ID: I20070517000341 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Brian D Williams |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1770569790 PECOS PAC ID: 5698873115 Enrollment ID: I20070607000162 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Christopher K Iorio |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1467456285 PECOS PAC ID: 9931187432 Enrollment ID: I20070607000503 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Alan J Watanabe |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1518961507 PECOS PAC ID: 3375521875 Enrollment ID: I20070607000545 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Mahendra V Govani |
|---|---|
| Provider Type | Practitioner - Nephrology |
| Provider Identifiers | NPI Number: 1669437398 PECOS PAC ID: 7517065774 Enrollment ID: I20070612000264 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Jason King |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1144294125 PECOS PAC ID: 6002907300 Enrollment ID: I20070801000006 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Kevin M Terrell |
|---|---|
| Provider Type | Practitioner - Addiction Medicine |
| Provider Identifiers | NPI Number: 1760591648 PECOS PAC ID: 3779674429 Enrollment ID: I20070809000282 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Katherine M Kelly |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1659315315 PECOS PAC ID: 4789775149 Enrollment ID: I20070814000653 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Anand Tandra |
|---|---|
| Provider Type | Practitioner - Hematopoietic Cell Transplantation And Cellular Therapy |
| Provider Identifiers | NPI Number: 1649495854 PECOS PAC ID: 2769574110 Enrollment ID: I20070815000594 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Daniel H Davis |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1154468270 PECOS PAC ID: 7911099569 Enrollment ID: I20070827000872 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | George F Albers |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1700923828 PECOS PAC ID: 2264524818 Enrollment ID: I20070827000894 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Gwendolyn S Kresovsky |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1649465410 PECOS PAC ID: 1658455175 Enrollment ID: I20080222000143 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Teresa A Oldham |
|---|---|
| Provider Type | Practitioner - Radiation Oncology |
| Provider Identifiers | NPI Number: 1841335874 PECOS PAC ID: 1951470202 Enrollment ID: I20080513000493 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Mark Allen Henderson |
|---|---|
| Provider Type | Practitioner - Radiation Oncology |
| Provider Identifiers | NPI Number: 1841370707 PECOS PAC ID: 2567537426 Enrollment ID: I20080812000849 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Ritu Rohatgi |
|---|---|
| Provider Type | Practitioner - Geriatric Medicine |
| Provider Identifiers | NPI Number: 1205841913 PECOS PAC ID: 6406835321 Enrollment ID: I20080819000736 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Deepak Jasuja |
|---|---|
| Provider Type | Practitioner - Nephrology |
| Provider Identifiers | NPI Number: 1548439870 PECOS PAC ID: 5890862593 Enrollment ID: I20080923000069 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Rachel R Reed |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1598924862 PECOS PAC ID: 2769534502 Enrollment ID: I20090709000082 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Barbara A Mclean |
|---|---|
| Provider Type | Practitioner - Hospitalist |
| Provider Identifiers | NPI Number: 1215192208 PECOS PAC ID: 1355493925 Enrollment ID: I20090711000011 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Michael D Stark |
|---|---|
| Provider Type | Practitioner - Psychiatry |
| Provider Identifiers | NPI Number: 1316101710 PECOS PAC ID: 8022164367 Enrollment ID: I20090928000731 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Tyrone C Manalac |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1174645063 PECOS PAC ID: 8628114121 Enrollment ID: I20091014000643 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | William H Stonehill |
|---|---|
| Provider Type | Practitioner - Urology |
| Provider Identifiers | NPI Number: 1427053511 PECOS PAC ID: 2961542238 Enrollment ID: I20091217000099 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Xiao Lin |
|---|---|
| Provider Type | Practitioner - Radiation Oncology |
| Provider Identifiers | NPI Number: 1750382586 PECOS PAC ID: 7810993995 Enrollment ID: I20091217000356 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Mary B Hensley |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1134206642 PECOS PAC ID: 6901948611 Enrollment ID: I20100119000344 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | David C Rau |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1033218664 PECOS PAC ID: 2769527738 Enrollment ID: I20100302000231 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Donald E Harris |
|---|---|
| Provider Type | Practitioner - Neurology |
| Provider Identifiers | NPI Number: 1508813858 PECOS PAC ID: 0547337537 Enrollment ID: I20100303000619 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | John P Winikates |
|---|---|
| Provider Type | Practitioner - Neurology |
| Provider Identifiers | NPI Number: 1386697712 PECOS PAC ID: 1951446863 Enrollment ID: I20100303000678 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Andrea Mernitz |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1962460964 PECOS PAC ID: 9537176755 Enrollment ID: I20100303000903 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Ann E James |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1285692921 PECOS PAC ID: 5890821839 Enrollment ID: I20100330000411 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | David J Porter |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1467410100 PECOS PAC ID: 9133255177 Enrollment ID: I20100330000448 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Jonathan S Crowder |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1598723959 PECOS PAC ID: 8325174261 Enrollment ID: I20100330000534 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Justin R Cooper |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1710121959 PECOS PAC ID: 5496885808 Enrollment ID: I20100611000055 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Susan W Feeney |
|---|---|
| Provider Type | Practitioner - Radiation Oncology |
| Provider Identifiers | NPI Number: 1750321469 PECOS PAC ID: 7012929466 Enrollment ID: I20100624000458 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Jeffrey Carson Hagedorn |
|---|---|
| Provider Type | Practitioner - Neurology |
| Provider Identifiers | NPI Number: 1679529879 PECOS PAC ID: 9638246622 Enrollment ID: I20100625000272 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Geoffrey S Raymer |
|---|---|
| Provider Type | Practitioner - Gastroenterology |
| Provider Identifiers | NPI Number: 1427094192 PECOS PAC ID: 4587769310 Enrollment ID: I20100722000442 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Brian J Niedbalski |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1124040589 PECOS PAC ID: 1759414857 Enrollment ID: I20100726000774 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Nadeem Ikhlaque |
|---|---|
| Provider Type | Practitioner - Hematology/oncology |
| Provider Identifiers | NPI Number: 1164477097 PECOS PAC ID: 5799798351 Enrollment ID: I20100810000162 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Timothy James Von Fange |
|---|---|
| Provider Type | Practitioner - Sports Medicine |
| Provider Identifiers | NPI Number: 1154461739 PECOS PAC ID: 6103992235 Enrollment ID: I20101112000848 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | David J Lee |
|---|---|
| Provider Type | Practitioner - General Surgery |
| Provider Identifiers | NPI Number: 1376657841 PECOS PAC ID: 5799972659 Enrollment ID: I20101206000273 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Michael J Dorenbusch |
|---|---|
| Provider Type | Practitioner - General Surgery |
| Provider Identifiers | NPI Number: 1265546725 PECOS PAC ID: 4789871310 Enrollment ID: I20101208001289 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | David M Thompson |
|---|---|
| Provider Type | Practitioner - General Surgery |
| Provider Identifiers | NPI Number: 1689788150 PECOS PAC ID: 4486842952 Enrollment ID: I20101228000297 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Monish Jain |
|---|---|
| Provider Type | Practitioner - Pediatric Medicine |
| Provider Identifiers | NPI Number: 1730292129 PECOS PAC ID: 9032247390 Enrollment ID: I20110602000165 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Evan T Russell |
|---|---|
| Provider Type | Practitioner - Cardiovascular Disease (cardiology) |
| Provider Identifiers | NPI Number: 1609039973 PECOS PAC ID: 7012194632 Enrollment ID: I20110608000564 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Suzanne Marie Ludlow |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1376874610 PECOS PAC ID: 1850578089 Enrollment ID: I20110615000515 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Usman Ashraf |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1326200973 PECOS PAC ID: 4789852377 Enrollment ID: I20110726000761 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Loren M Murray |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1255592309 PECOS PAC ID: 7719156645 Enrollment ID: I20110811000203 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Raymond Lee Kiser |
|---|---|
| Provider Type | Practitioner - Hospitalist |
| Provider Identifiers | NPI Number: 1245242452 PECOS PAC ID: 7214101666 Enrollment ID: I20111121000341 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Degaulle G Haile |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1881782506 PECOS PAC ID: 4688651375 Enrollment ID: I20130509000165 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Shelley Lynn Clark |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1093158925 PECOS PAC ID: 0840431003 Enrollment ID: I20130730000950 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Nandu Gourineni |
|---|---|
| Provider Type | Practitioner - Cardiovascular Disease (cardiology) |
| Provider Identifiers | NPI Number: 1033231220 PECOS PAC ID: 8224223466 Enrollment ID: I20130904000093 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Diane Watson Stone |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1386087385 PECOS PAC ID: 4880837103 Enrollment ID: I20130905000149 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Louise M Chaperon Jimenez |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1225393887 PECOS PAC ID: 9537319496 Enrollment ID: I20131001000194 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Justin J Burdick |
|---|---|
| Provider Type | Practitioner - General Surgery |
| Provider Identifiers | NPI Number: 1467621136 PECOS PAC ID: 8022242916 Enrollment ID: I20131008001383 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Alyssa M Lovell |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1922209709 PECOS PAC ID: 4981899788 Enrollment ID: I20131025001496 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Jyothi P Varanasi |
|---|---|
| Provider Type | Practitioner - Neurology |
| Provider Identifiers | NPI Number: 1245457886 PECOS PAC ID: 1052540580 Enrollment ID: I20140204000426 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Zachary T Siegel |
|---|---|
| Provider Type | Practitioner - Physical Medicine And Rehabilitation |
| Provider Identifiers | NPI Number: 1508185349 PECOS PAC ID: 6709029473 Enrollment ID: I20140702001480 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Lindsay Lee Anderson |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1831489756 PECOS PAC ID: 0345466546 Enrollment ID: I20140724000856 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Camra B Hussey |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1962791731 PECOS PAC ID: 8628201795 Enrollment ID: I20140806002429 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Sivagama Villa Ramasundaram |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1275811952 PECOS PAC ID: 5092932335 Enrollment ID: I20140811002385 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Chadi Saifan |
|---|---|
| Provider Type | Practitioner - Hospitalist |
| Provider Identifiers | NPI Number: 1740450477 PECOS PAC ID: 1052487923 Enrollment ID: I20140916001233 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Leesa D Mccauley |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1194936807 PECOS PAC ID: 7911053145 Enrollment ID: I20140929001557 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Kinsie L Fisher |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1306254131 PECOS PAC ID: 6608097795 Enrollment ID: I20141014000865 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Nicole Sichting |
|---|---|
| Provider Type | Practitioner - Certified Nurse Midwife (cnm) |
| Provider Identifiers | NPI Number: 1467830646 PECOS PAC ID: 7416268800 Enrollment ID: I20150626000291 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Patrick R Barrett |
|---|---|
| Provider Type | Practitioner - Gastroenterology |
| Provider Identifiers | NPI Number: 1861628661 PECOS PAC ID: 3779721543 Enrollment ID: I20150629001944 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Rachel B Cooper |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1700152162 PECOS PAC ID: 5799918561 Enrollment ID: I20150810002293 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Judith A Jackson |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1871961250 PECOS PAC ID: 7416264098 Enrollment ID: I20150915000390 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Samantha C Grider |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1013303569 PECOS PAC ID: 6709194475 Enrollment ID: I20150929002198 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Pamela R Spencer |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1316972029 PECOS PAC ID: 7416258959 Enrollment ID: I20151229000589 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Denise R Neawedde |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1093186751 PECOS PAC ID: 7810299377 Enrollment ID: I20151230001761 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Abhishek Vedavalli |
|---|---|
| Provider Type | Practitioner - Critical Care (intensivists) |
| Provider Identifiers | NPI Number: 1942536164 PECOS PAC ID: 4284877549 Enrollment ID: I20160126001454 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Daniel J Rauh |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1609120237 PECOS PAC ID: 2769380765 Enrollment ID: I20160127000353 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Nelda J Sturgill |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1952382632 PECOS PAC ID: 1254525561 Enrollment ID: I20160407001878 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Amy B Hale |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1134567779 PECOS PAC ID: 2860633138 Enrollment ID: I20160502000331 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Varun Gaur |
|---|---|
| Provider Type | Practitioner - Nephrology |
| Provider Identifiers | NPI Number: 1326326166 PECOS PAC ID: 0749588325 Enrollment ID: I20160607001566 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Angela Nielsen |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1457708885 PECOS PAC ID: 3072803790 Enrollment ID: I20160608000272 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Phyllis Harman |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1255787453 PECOS PAC ID: 1355632654 Enrollment ID: I20160616001026 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Evan David Allen |
|---|---|
| Provider Type | Practitioner - Neurology |
| Provider Identifiers | NPI Number: 1821101742 PECOS PAC ID: 8426945643 Enrollment ID: I20160728002098 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Danielle Elaine Keach |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1760935134 PECOS PAC ID: 9436443801 Enrollment ID: I20160808001290 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Andrea R Bukowski |
|---|---|
| Provider Type | Practitioner - Registered Dietitian Or Nutrition Professional |
| Provider Identifiers | NPI Number: 1366994485 PECOS PAC ID: 2668751413 Enrollment ID: I20161117002600 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Carlie Johnson |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1184086795 PECOS PAC ID: 8022390772 Enrollment ID: I20170113000059 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Sheilah Rauh |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1578931994 PECOS PAC ID: 3072898238 Enrollment ID: I20170330001661 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | John Tyler |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1447218797 PECOS PAC ID: 9133103393 Enrollment ID: I20170609000572 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Elias Khalaf |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1720420607 PECOS PAC ID: 2860618014 Enrollment ID: I20170619002113 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Janna Nickoll |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1376070847 PECOS PAC ID: 7416228762 Enrollment ID: I20170803003315 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Deepankar Sharma |
|---|---|
| Provider Type | Practitioner - Pulmonary Disease |
| Provider Identifiers | NPI Number: 1285947226 PECOS PAC ID: 0941572432 Enrollment ID: I20170817003217 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Chelsea A Spartz |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1285156893 PECOS PAC ID: 5395018097 Enrollment ID: I20170831000890 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Jordan Thompson |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1508389743 PECOS PAC ID: 2163796806 Enrollment ID: I20170920000457 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Julie Anne Simpson |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1598282774 PECOS PAC ID: 2264798206 Enrollment ID: I20171108001760 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Umair J Ashraf |
|---|---|
| Provider Type | Practitioner - Emergency Medicine |
| Provider Identifiers | NPI Number: 1255773396 PECOS PAC ID: 4284914326 Enrollment ID: I20171226000036 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Debra L Harmon |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1629576004 PECOS PAC ID: 1850651704 Enrollment ID: I20180214001352 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Vatsal Bajpai |
|---|---|
| Provider Type | Practitioner - Cardiovascular Disease (cardiology) |
| Provider Identifiers | NPI Number: 1013398353 PECOS PAC ID: 7810208238 Enrollment ID: I20180526000041 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Rachel Ann Kerschner |
|---|---|
| Provider Type | Practitioner - Hospitalist |
| Provider Identifiers | NPI Number: 1700102175 PECOS PAC ID: 4486900354 Enrollment ID: I20180706001726 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Erin M Cole |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1265813240 PECOS PAC ID: 1355654468 Enrollment ID: I20180709000138 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Baldeep Kaur |
|---|---|
| Provider Type | Practitioner - Hospitalist |
| Provider Identifiers | NPI Number: 1265817290 PECOS PAC ID: 1557667656 Enrollment ID: I20180709000673 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Herman S Dyal |
|---|---|
| Provider Type | Practitioner - Pulmonary Disease |
| Provider Identifiers | NPI Number: 1720335110 PECOS PAC ID: 9436382660 Enrollment ID: I20180806001017 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Jennifer L Thomas |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1962764472 PECOS PAC ID: 9133412158 Enrollment ID: I20180927000447 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Amy Diane Wilson |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1740764075 PECOS PAC ID: 8022360957 Enrollment ID: I20181004000329 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Rexanna L Tatlock |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1851877328 PECOS PAC ID: 8022361468 Enrollment ID: I20181031003138 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Trevor Dylan Whipker |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1326513268 PECOS PAC ID: 4688928666 Enrollment ID: I20181109000925 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Brandi Nicole Hart |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1982188223 PECOS PAC ID: 3779827811 Enrollment ID: I20181130001250 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Varrinder Singh Sandhu |
|---|---|
| Provider Type | Practitioner - Hospitalist |
| Provider Identifiers | NPI Number: 1598907289 PECOS PAC ID: 7517189277 Enrollment ID: I20181203000302 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Svetlana Varchenko |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1639652100 PECOS PAC ID: 5092059451 Enrollment ID: I20181212000841 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Karin Armstrong |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1609282060 PECOS PAC ID: 0840411955 Enrollment ID: I20190304000041 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Daphne Kyomuhendo Muzoora |
|---|---|
| Provider Type | Practitioner - Hospitalist |
| Provider Identifiers | NPI Number: 1467772624 PECOS PAC ID: 2769622554 Enrollment ID: I20190327001871 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Umer Farooq |
|---|---|
| Provider Type | Practitioner - Psychiatry |
| Provider Identifiers | NPI Number: 1487885513 PECOS PAC ID: 5092931956 Enrollment ID: I20190410000385 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Muhammad Rehan Azher Puri |
|---|---|
| Provider Type | Practitioner - Psychiatry |
| Provider Identifiers | NPI Number: 1972850170 PECOS PAC ID: 0749591055 Enrollment ID: I20190528000890 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | John Francis |
|---|---|
| Provider Type | Practitioner - Urology |
| Provider Identifiers | NPI Number: 1578906574 PECOS PAC ID: 9032358411 Enrollment ID: I20190712000730 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Aditya Chada |
|---|---|
| Provider Type | Practitioner - Pulmonary Disease |
| Provider Identifiers | NPI Number: 1245660257 PECOS PAC ID: 6406162825 Enrollment ID: I20190715000909 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Brittany L Morehead |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1528620325 PECOS PAC ID: 4385970557 Enrollment ID: I20190725001515 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | James Alan Martin |
|---|---|
| Provider Type | Practitioner - Hospitalist |
| Provider Identifiers | NPI Number: 1477916864 PECOS PAC ID: 5698052470 Enrollment ID: I20190730000795 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Misty Blackburn |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1770137044 PECOS PAC ID: 1254668510 Enrollment ID: I20190808002215 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Laurie Ann Black |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1376109736 PECOS PAC ID: 6709114796 Enrollment ID: I20190829001454 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Natalie Ann Green |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1477108660 PECOS PAC ID: 3870821762 Enrollment ID: I20190830001334 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Chelsi Stearns |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1306495890 PECOS PAC ID: 2163753377 Enrollment ID: I20191018000788 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Drew Hundley |
|---|---|
| Provider Type | Practitioner - Hospitalist |
| Provider Identifiers | NPI Number: 1598111817 PECOS PAC ID: 2860784451 Enrollment ID: I20191018002363 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Bradley Thomas York |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1144879115 PECOS PAC ID: 3375874530 Enrollment ID: I20191019000136 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Chandra Marlin |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1881237808 PECOS PAC ID: 0244562858 Enrollment ID: I20191031002292 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Amber Rose James |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1245874296 PECOS PAC ID: 6800224650 Enrollment ID: I20200310002232 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Andrea Kay Valentine |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1568094688 PECOS PAC ID: 9335577097 Enrollment ID: I20200312001039 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Nancy Scott |
|---|---|
| Provider Type | Practitioner - Pediatric Medicine |
| Provider Identifiers | NPI Number: 1932131588 PECOS PAC ID: 6901234202 Enrollment ID: I20200320000600 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Cheryl Harris |
|---|---|
| Provider Type | Practitioner - Pediatric Medicine |
| Provider Identifiers | NPI Number: 1841225075 PECOS PAC ID: 9234567546 Enrollment ID: I20200320000715 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Nicole Lurline Mensah-pike |
|---|---|
| Provider Type | Practitioner - Pediatric Medicine |
| Provider Identifiers | NPI Number: 1083009195 PECOS PAC ID: 1951739267 Enrollment ID: I20200320000748 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Jennifer R. Hartwell |
|---|---|
| Provider Type | Practitioner - Pediatric Medicine |
| Provider Identifiers | NPI Number: 1154586030 PECOS PAC ID: 4082042395 Enrollment ID: I20200320000989 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Rachel P Woods |
|---|---|
| Provider Type | Practitioner - Pediatric Medicine |
| Provider Identifiers | NPI Number: 1437415890 PECOS PAC ID: 6002247970 Enrollment ID: I20200508000881 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Emily B Banaschak |
|---|---|
| Provider Type | Practitioner - Hospitalist |
| Provider Identifiers | NPI Number: 1710418009 PECOS PAC ID: 4082983754 Enrollment ID: I20200508002826 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Nishchayjit Basra |
|---|---|
| Provider Type | Practitioner - Hospitalist |
| Provider Identifiers | NPI Number: 1205365475 PECOS PAC ID: 0244500775 Enrollment ID: I20200608000664 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Majd Kanbour |
|---|---|
| Provider Type | Practitioner - Interventional Cardiology |
| Provider Identifiers | NPI Number: 1427346501 PECOS PAC ID: 4284872680 Enrollment ID: I20200630002082 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Mazahir Ali |
|---|---|
| Provider Type | Practitioner - Hospitalist |
| Provider Identifiers | NPI Number: 1962927954 PECOS PAC ID: 2163784919 Enrollment ID: I20200701003358 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Kelsey Lynn Booth |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1356871198 PECOS PAC ID: 1850714783 Enrollment ID: I20200709003204 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Himani Sharma |
|---|---|
| Provider Type | Practitioner - Endocrinology |
| Provider Identifiers | NPI Number: 1811373657 PECOS PAC ID: 8921354143 Enrollment ID: I20200709003638 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Nafia Ashique |
|---|---|
| Provider Type | Practitioner - Hospitalist |
| Provider Identifiers | NPI Number: 1881126498 PECOS PAC ID: 3779820766 Enrollment ID: I20200721002466 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Mary Lucina Lucina Kessler |
|---|---|
| Provider Type | Practitioner - Certified Clinical Nurse Specialist (cns) |
| Provider Identifiers | NPI Number: 1619049301 PECOS PAC ID: 5597181727 Enrollment ID: I20200818002154 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Sasha Edmondson |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1184237067 PECOS PAC ID: 1052731585 Enrollment ID: I20201021001999 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Kelly Marie Anderson |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1184255408 PECOS PAC ID: 6507276466 Enrollment ID: I20201104000176 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Amy Joyce Patterson |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1376159442 PECOS PAC ID: 6800207366 Enrollment ID: I20201204001937 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Alison Renee Ortman |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1508470626 PECOS PAC ID: 7810309663 Enrollment ID: I20201218001884 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Lacey Wills |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1275135212 PECOS PAC ID: 2769895036 Enrollment ID: I20210105001632 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Hoda K Elzawahry |
|---|---|
| Provider Type | Practitioner - Neurology |
| Provider Identifiers | NPI Number: 1972791002 PECOS PAC ID: 4183751241 Enrollment ID: I20210112001281 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Vivek Rajani |
|---|---|
| Provider Type | Practitioner - Psychiatry |
| Provider Identifiers | NPI Number: 1912393091 PECOS PAC ID: 5890084859 Enrollment ID: I20210121001843 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Elaina Lynn Weiss |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1295315372 PECOS PAC ID: 2860801974 Enrollment ID: I20210430001932 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Carol Anne Hahn |
|---|---|
| Provider Type | Practitioner - Radiation Oncology |
| Provider Identifiers | NPI Number: 1982799698 PECOS PAC ID: 4789725045 Enrollment ID: I20210518002311 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Brian Jones |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1629575113 PECOS PAC ID: 6709132103 Enrollment ID: I20210716001351 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Brenden Barker |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1912439316 PECOS PAC ID: 4981953502 Enrollment ID: I20210729002500 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Peter M O'day |
|---|---|
| Provider Type | Practitioner - Hospitalist |
| Provider Identifiers | NPI Number: 1093219487 PECOS PAC ID: 8426451394 Enrollment ID: I20210729002536 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Stacy Spencer |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1952985632 PECOS PAC ID: 8628478708 Enrollment ID: I20210917001830 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Manjusha Thenozhiyil |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1437656105 PECOS PAC ID: 1850798893 Enrollment ID: I20210917002402 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Heather Michelle Gross |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1851066898 PECOS PAC ID: 6305243825 Enrollment ID: I20210927002252 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Erica Leigh Daily |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1629642509 PECOS PAC ID: 4789082991 Enrollment ID: I20211001001145 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Jennifer Marie Robinson |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1598431595 PECOS PAC ID: 4688072812 Enrollment ID: I20211001001871 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Jasmine Kai Milligan |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1962079988 PECOS PAC ID: 2163820333 Enrollment ID: I20211004000602 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Tennie Smith |
|---|---|
| Provider Type | Practitioner - Hospitalist |
| Provider Identifiers | NPI Number: 1861854721 PECOS PAC ID: 9931491156 Enrollment ID: I20211006003297 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Samantha J Fleckenstein |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1356848386 PECOS PAC ID: 9133476906 Enrollment ID: I20211104001539 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Suzanne Keller Roberts |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1588328025 PECOS PAC ID: 4587053574 Enrollment ID: I20211112001284 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Swati Laroia Coon |
|---|---|
| Provider Type | Practitioner - Neurology |
| Provider Identifiers | NPI Number: 1306284765 PECOS PAC ID: 8224255492 Enrollment ID: I20211118000856 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Kiran Chintam |
|---|---|
| Provider Type | Practitioner - Nephrology |
| Provider Identifiers | NPI Number: 1982930285 PECOS PAC ID: 9032367255 Enrollment ID: I20211206000406 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Kirsten N Gilmore |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1881363786 PECOS PAC ID: 7113318288 Enrollment ID: I20211228000850 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Suzannah Mckenzie Brown |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1215696208 PECOS PAC ID: 6709271950 Enrollment ID: I20220324002508 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Cory Banaschak |
|---|---|
| Provider Type | Practitioner - General Surgery |
| Provider Identifiers | NPI Number: 1306377874 PECOS PAC ID: 5294004966 Enrollment ID: I20220516001932 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Amy Dawn Mcdonald |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1245980911 PECOS PAC ID: 9436539384 Enrollment ID: I20220708002598 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Michelle Smith |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1194477588 PECOS PAC ID: 4789064551 Enrollment ID: I20220711002343 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Justin Lee |
|---|---|
| Provider Type | Practitioner - General Surgery |
| Provider Identifiers | NPI Number: 1811359177 PECOS PAC ID: 5092116913 Enrollment ID: I20220727002053 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Carolyn Behling |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1053052159 PECOS PAC ID: 8325421126 Enrollment ID: I20220811000919 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Samantha A Loza |
|---|---|
| Provider Type | Practitioner - Pediatric Medicine |
| Provider Identifiers | NPI Number: 1982263307 PECOS PAC ID: 4385076306 Enrollment ID: I20220819002349 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Nathan Buell |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1407586431 PECOS PAC ID: 8527441708 Enrollment ID: I20220822000857 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Smit Pratik Mehta |
|---|---|
| Provider Type | Practitioner - Hospitalist |
| Provider Identifiers | NPI Number: 1689167215 PECOS PAC ID: 8022491125 Enrollment ID: I20220823002539 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Rebecca Metz |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1710655162 PECOS PAC ID: 9537543954 Enrollment ID: I20220903000343 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Casey Gail Turner |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1851022784 PECOS PAC ID: 4587049432 Enrollment ID: I20220914000660 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Chelsie Lynn Brady |
|---|---|
| Provider Type | Practitioner - Hospitalist |
| Provider Identifiers | NPI Number: 1114486966 PECOS PAC ID: 5698000693 Enrollment ID: I20220914001913 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Paulette Padilla Shields |
|---|---|
| Provider Type | Practitioner - Pediatric Medicine |
| Provider Identifiers | NPI Number: 1760042162 PECOS PAC ID: 3678905676 Enrollment ID: I20221005001680 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Preetam R Bollampally |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1386059756 PECOS PAC ID: 3274824644 Enrollment ID: I20221110001309 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Jamie Danielle Doughty |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1144952342 PECOS PAC ID: 0143699611 Enrollment ID: I20221206002066 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Neil Amin |
|---|---|
| Provider Type | Practitioner - Hospitalist |
| Provider Identifiers | NPI Number: 1023676673 PECOS PAC ID: 8729315692 Enrollment ID: I20221212002018 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Jodi G Herche |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1184348377 PECOS PAC ID: 6406225531 Enrollment ID: I20221213001632 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Albert Attah-kofi Sey |
|---|---|
| Provider Type | Practitioner - Cardiovascular Disease (cardiology) |
| Provider Identifiers | NPI Number: 1396051785 PECOS PAC ID: 0143464271 Enrollment ID: I20221223001314 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Akhila Ramayapally |
|---|---|
| Provider Type | Practitioner - Endocrinology |
| Provider Identifiers | NPI Number: 1356773485 PECOS PAC ID: 5991057895 Enrollment ID: I20230110000400 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Kyra Betts |
|---|---|
| Provider Type | Practitioner - Certified Nurse Midwife (cnm) |
| Provider Identifiers | NPI Number: 1750084455 PECOS PAC ID: 2567837628 Enrollment ID: I20230406002749 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Andrew Barbrow Lobl |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1598865503 PECOS PAC ID: 1658335468 Enrollment ID: I20230504000527 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Melissa Andrea Martinez Mateo |
|---|---|
| Provider Type | Practitioner - Gastroenterology |
| Provider Identifiers | NPI Number: 1003124280 PECOS PAC ID: 1254570799 Enrollment ID: I20230515000523 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Manjula V Burri |
|---|---|
| Provider Type | Practitioner - Cardiovascular Disease (cardiology) |
| Provider Identifiers | NPI Number: 1619172228 PECOS PAC ID: 1658311873 Enrollment ID: I20230608000665 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Khurram Nazir |
|---|---|
| Provider Type | Practitioner - Neurology |
| Provider Identifiers | NPI Number: 1619261252 PECOS PAC ID: 1951615871 Enrollment ID: I20230623002334 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Betsy Place |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1477110955 PECOS PAC ID: 0345576849 Enrollment ID: I20230718000444 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Autumn Burkman |
|---|---|
| Provider Type | Practitioner - Certified Nurse Midwife (cnm) |
| Provider Identifiers | NPI Number: 1144907155 PECOS PAC ID: 3971964503 Enrollment ID: I20230731000942 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Najib Murr |
|---|---|
| Provider Type | Practitioner - Neurology |
| Provider Identifiers | NPI Number: 1831319862 PECOS PAC ID: 6800067265 Enrollment ID: I20230808003947 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Iyabo Olatunde |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1275160202 PECOS PAC ID: 7214351741 Enrollment ID: I20230824000432 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Ray B Terrell |
|---|---|
| Provider Type | Practitioner - Urology |
| Provider Identifiers | NPI Number: 1447257415 PECOS PAC ID: 2769448166 Enrollment ID: I20230912001515 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Shashank Sarvepalli |
|---|---|
| Provider Type | Practitioner - Gastroenterology |
| Provider Identifiers | NPI Number: 1124445002 PECOS PAC ID: 7618243445 Enrollment ID: I20230912002612 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Ryan William Zipper |
|---|---|
| Provider Type | Practitioner - Urology |
| Provider Identifiers | NPI Number: 1356722698 PECOS PAC ID: 3577863828 Enrollment ID: I20231009000750 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Alivia S Hoeltke |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1154104180 PECOS PAC ID: 0244686731 Enrollment ID: I20231019000368 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Aileen Cangiano-heath |
|---|---|
| Provider Type | Practitioner - Neurology |
| Provider Identifiers | NPI Number: 1609074616 PECOS PAC ID: 9234544735 Enrollment ID: I20231019003123 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Praveen Kumar Vemuri |
|---|---|
| Provider Type | Practitioner - Neurology |
| Provider Identifiers | NPI Number: 1598104234 PECOS PAC ID: 6204138084 Enrollment ID: I20231103000938 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Amie Jo Jarosz |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1861279325 PECOS PAC ID: 8123475670 Enrollment ID: I20231106002268 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Tim Lekic |
|---|---|
| Provider Type | Practitioner - Neurology |
| Provider Identifiers | NPI Number: 1578855151 PECOS PAC ID: 0941580096 Enrollment ID: I20231113002215 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Teresa Mangin |
|---|---|
| Provider Type | Practitioner - Neurology |
| Provider Identifiers | NPI Number: 1144385352 PECOS PAC ID: 9032284104 Enrollment ID: I20231202000182 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Vijaya K Vudathaneni |
|---|---|
| Provider Type | Practitioner - Hospitalist |
| Provider Identifiers | NPI Number: 1457623548 PECOS PAC ID: 2365669082 Enrollment ID: I20231204002103 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Brittany Laine Andrus |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1679350359 PECOS PAC ID: 5294184974 Enrollment ID: I20231206002192 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Vadak Ranganathan |
|---|---|
| Provider Type | Practitioner - Neurology |
| Provider Identifiers | NPI Number: 1992773212 PECOS PAC ID: 5092841387 Enrollment ID: I20231211003120 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Lorie Ann Anderson |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1679097588 PECOS PAC ID: 8921374026 Enrollment ID: I20240112000321 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Jennifer M Whitaker |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1245005792 PECOS PAC ID: 1456704576 Enrollment ID: I20240125000536 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Marcella Ann Ross |
|---|---|
| Provider Type | Practitioner - Certified Clinical Nurse Specialist (cns) |
| Provider Identifiers | NPI Number: 1518576891 PECOS PAC ID: 1254590607 Enrollment ID: I20240125002946 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Bethany Peetz |
|---|---|
| Provider Type | Practitioner - Mental Health Counselor |
| Provider Identifiers | NPI Number: 1215105770 PECOS PAC ID: 3072977677 Enrollment ID: I20240206000798 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
| Provider Name | Leah Foster |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1689451411 PECOS PAC ID: 9032554225 Enrollment ID: I20240227004039 |
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
News Archive
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
A University of Central Florida professor has invented a way to use light to continuously monitor a surgical patient's blood, for the first time providing a real-time status during life-and-death operations.
BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.
The addition of the glucagon-like peptide 1 receptor agonist liraglutide improves short-term outcomes and treatment satisfaction in patients who have uncontrolled Type 2 diabetes despite high doses of insulin, shows a randomised trial.
The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.
› Verified 2 days ago
Promptmed Urgent Care Center Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 2502 25th St, Columbus, IN 47201 Phone: 812-372-8883 Fax: 812-372-8964 | |
Columbus Regional Health Physicians, Llc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 2325 18th St, Suite 130, Columbus, IN 47201 Phone: 812-379-2020 | |
Centerstone Health Services, Inc. Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 720 N Marr Rd Ste A, Columbus, IN 47201 Phone: 812-314-3400 Fax: 812-376-4875 | |
Columbus Regional Health Physicians, Llc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 2326 18th St, Suite 120, Columbus, IN 47201 Phone: 812-372-1570 | |
Columbus Regional Health Physicians, Llc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 2326 18th St, Suite 210, Columbus, IN 47201 Phone: 812-372-8426 | |
Ourhealth Physicians Group, Llc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 6125 Inwood Dr, Columbus, IN 47201 Phone: 866-434-3255 | |
Cummins Health Center Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 806 Jackson St, Columbus, IN 47201 Phone: 812-748-3412 Fax: 812-748-3413 |